Trial Profile
A Multi-Center, Open-Label, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Inodiftagene-vixteplasmid (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms LAPC-BC-819
- Sponsors Anchiano Therapeutics Israel
- 08 Mar 2019 Status changed from active, no longer recruiting to discontinued. As per NCT01413087 the study was stopped: Due to the Sponsor's decision, only 12 patients were randomized and completed the study.
- 09 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Mar 2012 Planned number of patients changed from 150 to 70 as reported by ClinicalTrials.gov.